Oncoleader

I want to meet you at ATW in Dallas in January and I can get you a HUGE discount on your ticket. I'm going to Advanced Therapies Week (ATW) in Dallas this January (Jan 20-23) and its the perfect opportunity to connect with the leaders in the CGT space. Thanks to Phacilitate, I’ll be there and look forward to meaningful conversations about the challenges and opportunities shaping our industry. If you’re attending, let’s connect - I’d love to meet you and hear about your work. If you want to attend and haven't gotten your ticket yet, I've partnered with Phacilitate to offer a 30% discount on your ticket. Use code JEFF30 at checkout for 30% off your ticket. I'll see you in Dallas! #ATW25 #AdvancedTherapies #Biotech

So, everyone is wondering: "What does the future of cell therapy look like?" Well, I'm heading to Phacilitate’s Advanced Therapies Week 2025 in Dallas, TX to find out. Do you want a front-row seat to see the leading experts and top minds in the field discuss their thoughts on the future of the field? Get your ticket now and secure your spot! Use code "JEFFREY30" at checkout to get 30% off your ticket. Link here: https://ow.ly/Z4Ff50TLIl2 PLUS! I'll be hosting their AT-TV live coverage! When is it? January 20-23 Where is it? Dallas, TX. Here's what you can expect. 🟢 Access to top minds shaping the future of advanced therapies 🟢 Opportunities for partnerships, collaborations, and investment 🟢 Networking with industry leaders from across the world Come be a part of this incredible event #ATW25 #AdvancedTherapies #Biotech

Are NK Cell Engagers about to rise to prominence in oncology? New data sparks interest. --- So, there seems to be a strong trend in oncology towards bispecific antibodies, either in the form of immune cell engagers (targeting a tumor antigen and an immune cell receptor), or dual-targeting antibodies (targeting two unique therapeutic targets like PD-1 and VEGF, for example). Well, the vast majority of FDA approved bispecifics for cancer therapy are classified as T cell engagers. These things are antibodies that bind to: i) a tumor-associated antigen and ii) CD3 on T cells, inducing T cell-mediated cancer killing. While T cell engagers display potent therapeutic activity, they have two notable limitations: i) they can cause cytokine release syndrome (very toxic), and ii) they're only able to induce T cell killing against antigen-positive cells, leaving room for antigen-negative cells to escape - RESISTANCE! NK cell engagers, on the other hand, don't really suffer from either of these limitations (as much) because: i) they are much safer because NK cells tend NOT to induce CRS, and ii) they can - IN THEORY - cause NK cells to target cancer cells in an antigen-independent manner. Despite this, it seems as though NK cell engagers don't attract as much attention as T cell engagers...why? Well, in this week's Trends in Oncology video at Oncoleader, I explain exactly why T cell engagers tend to overshadow their NK counterpart and then discuss some very new data from Innate Pharma that could very well begin to shift this paradigm. full video here: https://lnkd.in/e6DxbT5B I hope to see you there! Key topics discussed: 🔴 NK Cell Engager Basics – why should we even care about them…? 🔴 Overview of the NK Cell Engager field - who is making these things? 🔴 The unique aspect of Innate Pharma's platform 🔴 Key findings from Innate's paper published last week 🔴 Potential implications for the future of oncology Feel free to share the video with colleagues, friends, or anyone who might find it valuable or interesting! #oncology #innatepharma #bispecificantibodies

The "Fourth Wave" of drug development is about to transform oncology. Over the past few months, several major biotech and pharmaceutical companies have made headlines with their advancements in multispecific protein therapeutics, a new class of drugs poised to challenge the dominance of Merck’s blockbuster oncology drug, Keytruda. The landscape is shifting with the emergence of multispecific therapies, particularly bispecific antibodies that target multiple pathways simultaneously. Several recent developments have made it clear that these newcomers represent a serious threat to Keytruda’s throne, and companies like Summit Therapeutics, AbbVie, BioNTech, and Merck itself are racing to develop or acquire these innovative treatments. I have just released a new video where I break down these recent developments and explain exactly why this trend is occurring. You can find it here: https://lnkd.in/esKyMZ95 Be sure to subscribe to the newsletter to be notified whenever I publish new episodes or release new video courses (link on homepage).

A new era of cancer therapy has begun. Over the past few months, several major biotech and pharmaceutical companies have made headlines with their advancements in multispecific protein therapeutics, a new class of drugs poised to challenge the dominance of Merck’s blockbuster oncology drug, Keytruda. The landscape is shifting with the emergence of multispecific therapies, particularly bispecific antibodies that target multiple pathways simultaneously. Several recent developments have made it clear that these newcomers represent a serious threat to Keytruda’s throne, and companies like Summit Therapeutics, AbbVie, BioNTech, and Merck itself are racing to develop or acquire these innovative treatments. Watch the full episode here: https://lnkd.in/esKyMZ95 #oncoleader #trendsinoncology

HUGE NEWS. Introducing: Emerging Biotech Today’s Insights Into Tomorrow’s Cancer Therapies. I have a huge announcement to make. I am launching my video series called "Emerging Biotech" where we are going to uncover the future of oncology by analyzing the most prominent biotech startups in the industry. All of these companies are super early in development but are gaining an absolutely absurd amount traction in terms of investment - most have over $100M in funding in their first 3 years. With the field evolving so quickly, these newcomers are going to dominate the landscape in the next 2-5 years. So, in order to not fall behind, you need to stay on top of the emerging biotech. Let's do it together. --- Episode 1: Avenzo Therapeutics (https://lnkd.in/eqcGWuph) In this first episode, I’m examining Avenzo Therapeutics – a company that is absolutely poised to disrupt the industry. Avenzo has raised over 550 million dollars in three funding rounds over the course of the last 2.5 years to advance their small molecule CDK2 inhibitor making them one of the most well-funded biotech startups in the world. Founded in San Francisco, CA in 2022, Avenzo stands out to me for three key reasons: First, its leadership: Two highly renowned scientists with a long list of successes are steering the ship. Second, its financial backing: Avenzo has secured substantial funding – they’re absolutely loaded – providing a robust foundation for its ambitious goals. Third, its promising, data-driven platform and strategic approach to patient selection has set them up for clinical and commercial success. With a strong scientific rationale as their guide, Avenzo is focusing on targeting "CDK2-dependent" cancers, primarily hormone receptor-positive breast cancer and CCNE1-amplified solid tumors, including ovarian cancer. While they have not gathered any clinical data yet, their lead compound, AZVO-021, has shown promising single-agent and synergistic activity across multiple preclinical models and it appears to be very safe. Join me as we dissect Avenzo’s science, strategy, and potential impact on the oncology landscape. This is Emerging Biotech: Today’s Insights Into Tomorrow’s Cancer Therapies. #emergingbiotech

BREAKING NEWS: Autolus' CAR-T Cell Therapy Receives FDA Approval: A Breakdown Last week Friday (11/8), London-based biotech Autolus announced that they had received FDA approval for their autologous CAR-T cell therapy AUCATZYL (obe-cel) for use in adult r/r B-ALL. In the US and EU there are about 8,500 patients diagnosed with r/r B-ALL annually and about 3,000 of them are in the relapsed/refractory setting and would qualify for obe-cel treatment. So, this is amazing news for the patients and the company – congrats to both! I have just released a full explainer video on my platform (Oncleader - link at bottom of this post) where I layout: - The clinical data that led to the approval - How Autolus' "Fast-Off" CAR technology makes their CAR-T cells so effective. - The implications of this approval for cancer and autoimmune patients 📹 📽 Full video (7 min) - (link here: https://lnkd.in/evcAaPBU)

“Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development” $COEP is pleased to bring you Press on our #Phase1 #Covid_19 treatment: https://lnkd.in/ewqZpFKd #Coeptis #Therapeutics #DVX201 #immunotherapy #NKCellTherapy

POSITIVE CLINICAL DATA FOR CAR-T THERAPY: My 3-Minute Breakdown ARCELLX just released a sneak preview of their most recent clinical data that has many people in the industry buzzing. The data come from a phase II trial of 58 patients with relapsed/refractory multiple myeloma that were treated with their BCMA-targeting "ddCAR-T cell" platform called anito-cel. What exactly are ddCAR-T cells? What does the data show? Why is it important? Check out my 3-minute breakdown to get the full scoop! --- ❗❗P.S. if you like this kind of content (oncology news delivered in video format), send me a direct message, I have a very special offer for you!

EMERGING TREND IN BIOTECH: Targeted Protein Degraders for Immunology I've been noticing a small but interesting trend lately, and it could be the start of something much bigger: targeted protein degradation for treating immunological disorders (think inflammatory diseases and autoimmune conditions). For those unfamiliar, targeted protein degraders (TPDs) are synthetic compounds (some are small molecules, others are proteins) designed to degrade specific proteins in the body. They target disease-causing proteins that are tough to hit with more "traditional" methods like antibodies or small molecules. It looks like TPDs are starting to gain traction in the world of inflammation and immunology. Definitely something to keep an eye on! Check out this short video to learn more.